Kalaris Therapeutics grants 9,000 stock options

Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock.

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock. The options have an exercise price of $4.7200 per share and expire on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service.

Insider Trade Summary

Grant/Award: 9,000 shares

Grant/Award 1 txn

Insider Ferrara Napoleone

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Option grant size: 9,000 shares Exercise price: $4.7200 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 9,000 shares Stock Option (Right to Buy) granted to director

Exercise price $4.7200 per share Exercise price for 9,000 stock options

Expiration date June 2, 2036 Option award expiry

Vesting date Earlier of June 3, 2027 or 2027 meeting Full vesting, subject to continued service

Post-transaction options held 9,000 options Total derivative securities following this grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"Security title reported as Stock Option (Right to Buy) for 9,000 shares"

exercise price financial

"The option has an exercise price of $4.7200 per share of common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The options carry an expiration date of June 2, 2036 for the award"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"The underlying security title is listed as Common Stock for this option"

vest in full financial

"The shares underlying the option are scheduled to vest in full on the earlier date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kalaris Therapeutics (KLRS) report for Ferrara Napoleone?

Kalaris Therapeutics reported that director Ferrara Napoleone received a grant of stock options for 9,000 shares. These options give the right to buy common stock at a fixed price and represent a compensation-related award rather than an open-market purchase or sale.

What are the key terms of Ferrara Napoleone’s stock option grant at KLRS?

Ferrara Napoleone’s grant covers 9,000 shares of Kalaris Therapeutics common stock with an exercise price of $4.7200 per share. The options expire on June 2, 2036, giving a long window to exercise once the award has vested under the stated conditions.

When do Ferrara Napoleone’s Kalaris Therapeutics options vest?

The 9,000-share option award is scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on Ferrara Napoleone’s continued service with the company through that vesting date.

Is Ferrara Napoleone’s Form 4 transaction a buy or a compensation grant at KLRS?

Ferrara Napoleone’s Form 4 reports a compensation-related grant, coded as a grant, award, or other acquisition. It reflects an option award to acquire 9,000 shares at $4.7200 per share, not an open-market purchase or sale of Kalaris Therapeutics stock.

How many Kalaris Therapeutics derivative securities does Ferrara Napoleone hold after this filing?

After this reported transaction, Ferrara Napoleone holds 9,000 stock options in Kalaris Therapeutics, corresponding to 9,000 underlying shares of common stock. This reflects the full amount of the newly granted award reported in the Form 4 for this director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferrara Napoleone

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.72	06/03/2026		A		9,000		(1)	06/02/2036	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brett Hagen, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)